Amarin | AMRN - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
AbbVie USD 3.63B 54M 2026-06
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
AstraZeneca USD 5.8B 735M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
DBV Technologies USD 13.4M 8.14M 2026-03
GlaxoSmithKline GBP 2.19B 75M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06